Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
84 Results for "
microglial cell
" in MedChemExpress (MCE) Product Catalog:
Products (84)
84 Results for "microglial cell" in MCE Product Catalog:
Cat. No.: HY-135556A
CAS No.: 107674-50-0
Research Areas:
Norfluoxetine oxalate is the active metabolite of the antidepressant Fluoxetine (HY-B0102); it is also a TREK-2 K2P potassium channel inhibitor. Norfluoxetine oxalate exhibits neuroimmunological activity, induces apoptosis in primary microglial cells, and inhibits the release of pro-inflammatory factors. Norfluoxetine oxalate inhibits high-threshold voltage-gated Ca 2+ currents in neurons with an EC50 of 20.4 μM. Norfluoxetine oxalate can be used in research related to depression, ischemic stroke, and epilepsy .
Cat. No.: HY-159152
CAS No.: 2226535-25-5
Target:
Research Areas:
PQM-164 (Compound 3e) has antioxidant activity (IC50: 0.93 μM for DPPH radical). PQM-164 shows anti-inflammatory activity against 6-OHDA (HY-B1081A)-induced neuronal damage in activated microglial cells. PQM-164 decreases the accumulation of α-synuclein. PQM-164 promotes nuclear translocation of Nrf2 and its transcriptional activity. PQM-164 can be used for research of Parkinson’s disease .
Cat. No.: HY-W011235R
CAS No.: 57226-68-3
Research Areas:
Norfluoxetine hydrochloride (Standard) is the analytical standard of Norfluoxetine hydrochloride (HY-W011235). This product is intended for research and analytical applications. Norfluoxetine hydrochloride is the active metabolite of the antidepressant Fluoxetine (HY-B0102); it is also a TREK-2 K2P potassium channel inhibitor. Norfluoxetine hydrochloride exhibits neuroimmunological activity, induces apoptosis in primary microglial cells, and inhibits the release of pro-inflammatory factors. Norfluoxetine hydrochloride inhibits high-threshold voltage-gated Ca 2+ currents in neurons with an EC50 of 20.4 μM. Norfluoxetine hydrochloride can be used in research related to depression, ischemic stroke, and epilepsy .
Cat. No.: HY-178144
Research Areas:
FPR2 agonist 5 is a selective Formyl Peptide Receptor 2 (FPR2) agonist. FPR2 agonist 5 induces Ca 2+ mobilization in FPR2-HL60 transfected cells with an EC50 of 1.2 μM and causes FPR2 desensitization with an IC50 of 0.32 μM. FPR2 agonist 5 exerts neuroprotective effects by mitigating LDH release, NO production, IL-1β, IL-6, IL-33, and IL-10 levels in LPS (HY-D1056)-induced mouse primary microglial cells. FPR2 agonist 5 can be used for the study of neuroinflammatory-related diseases .
Cat. No.: HY-161972
Target:
Research Areas:
ZX782 is a HyT GPX4 degrader and a ferroptosis inducer, which induces GPX4 degradation and significantly increases lipid ROS accumulation in HT1080 cells. ZX782 can be used to treat AD by reducing the size and/or number of brain amyloid plaques and by inhibiting the spread of IL-1beta-positive microglial-like cells around amyloid plaques. ZX782 is labeled with hydrophobic benzyl alcohol (HBA) and appears bright blue under acidic conditions, which can be used for quantitative determination . ZX782 is composed of target protein ligand (red part) ML-210 (HY-100003), PROTAC linker (black part) Bromo-PEG2-CH2-Boc (HY-141371) and Hty molecule (blue part) Adamantan-1-ylmethanamine (HY-W037848). The conjugate consisting of Hyt and linker parts is Adamantan-C-amide-PEG2-C-Br (HY-161974), and the activity control of the target protein ligand is Hydroxyl-ML-210 (HY-161973).
Cat. No.: HY-P992516
Target:
Research Areas:
Cat. No.: HY-180997
Target:
Research Areas:
Aβ aggregation-IN-5 is a brain-penetrant amyloid-β aggregation inhibitor. Aβ aggregation-IN-5 inhibits Aβ aggregation/oligomerization, rescues cells from AB/ROS toxicity and reduces microglial activation/NO production. Aβ aggregation-IN-5 reduces amyloid burden, neuroinflammation, microglial activation in APP/PSEN1 mice. Aβ aggregation-IN-5 can be used for the research of Alzheimer's disease .
Target:
Cat. No.: HY-N21887
CAS No.: 105214-48-0
Cat. No.: HY-164641
CAS No.: 2459994-71-7
Target:
Research Areas:
GPR34 agonist 1 is a G-protein coupled receptor 34 agonist that enhances fibrillar Aβ uptake in mouse primary microglia with an EC50 of 5 nM .GPR34 agonist 1 selectively activates Gi/o-coupled GPR34, reduces intracellular cyclic adenosine monophosphate levels, and requires functional TREM2 signaling .GPR34 agonist 1 induces microglial Aβ fibril phagocytosis and chemotaxis, enhances microglial uptake and clearance of amyloid β fibrils, and increases microglial Aβ fibril uptake in vivo and in human induced pluripotent stem cell-derived microglia .GPR34 agonist 1 can be used for the research of Alzheimer disease .
Cat. No.: HY-N21923
CAS No.: 126239-88-1
Target:
Cat. No.: HY-B1114A
CAS No.: 62783-47-5
Synonyms: AR-DF 26 sodium
Target:
Potassium Channel Free Radical Scavengers ERK STAT NF-κB COX Interleukin Related Reactive Oxygen Species (ROS)
Research Areas:
Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
Gliquidone sodium (AR-DF 26 sodium) can bind to the pancreatic β-cells and increases insulin release to regulate blood glucose levels. Gliquidone sodium significantly decreases LPS (HY-D1056)-induced proinflammatory responses and inhibits ERK/STAT3/NF-κB phosphorylation in BV2 microglial cells. Gliquidone sodium can suppress microgliosis, microglial hypertrophy mediated by LPS, and proinflammatory cytokine COX-2 and IL-6 levels in murine model. Gliquidone sodium also exhibits good anticancer activity in lung carcinoma cells. Gliquidone sodium has antioxidant property. Gliquidone sodium can be studied in research for type 2 diabetes and cancers .
Cat. No.: HY-D3180
CAS No.: 1201643-01-7
Cat. No.: HY-N19854
CAS No.: 2097442-40-3
Target:
Cat. No.: HY-182943
Target:
Research Areas:
BTK-IN-49 is a selective, orally active and brain-penetrant BTK inhibitor with an IC50 of 0.14 nM. BTK-IN-49 binds to BTK and blocks B-cell receptor and Fcγ receptor signaling. BTK-IN-49 inhibits the proliferation of CNS-compartmentalized B-cells and FcγR-induced microglial proliferation in a BTK-dependent manner. BTK-IN-49 can be used for the study of multiple sclerosis .
Cat. No.: HY-N15564
CAS No.: 31554-34-4
Category:
Target:
Cat. No.: HY-112369
CAS No.: 331662-51-2
Target:
Research Areas:
LDDN-0003499 is a Src family tyrosine kinase inhibitor and anti-inflammatory agent. LDDN-0003499 reduces basal and Aβ-stimulated levels of active, phosphorylated Lyn and Src kinases, and attenuates Aβ-stimulated secretion of pro-inflammatory cytokines TNFα and IL-6 in microglial cells. LDDN-0003499 can be used for the research of Alzheimer's disease .
Cat. No.: HY-189150
CAS No.: 1643925-08-9
Research Areas:
NSP-116 is an orally active antioxidant and neuroprotective agent. NSP-116 protects corneal epithelial cells from UV-A and blue light LED-induced photo-oxidative damage. NSP-116 scavenges DPPH, superoxide anion, and hydroxyl radicals, inhibits light-induced ROS production in photoreceptor cells, and inhibits lipid peroxidation in retinal homogenates. NSP-116 prevents light-induced photoreceptor cell death and retinal degeneration, and inhibits intracellular Fe 2+ accumulation, autophagy, apoptosis, p38 phosphorylation, and microglial/macrophage activation. NSP-116 exerts neuroprotective effects in hemorrhagic stroke models. NSP-116 can be used for research on photokeratitis, dry age-related macular degeneration, and intracranial hemorrhage .
Cat. No.: HY-182702
CAS No.: 1214405-38-5
Target:
Research Areas:
As48 is a selective TREM2 agonist with a KD value of 12.48 μM in TRIC binding assay. As48 binds near the TREM2 cleavage region, forms hydrogen bonds with Gly68, reduces conformational flexibility in regions 58-102, restricts protease accessibility to the cleavage site. As48 activates SYK phosphorylation, enhances microglial phagocytosis, and induces downstream calcium signaling in TREM2-expressing cells. As48 inhibits TREM2 ectodomain shedding without affecting ADAM10/17 protease activities. As48 can be used for the research of Alzheimer's disease .
Cat. No.: HY-114153R
CAS No.: 1303420-67-8
Target:
Research Areas:
PLX5622 (Standard) is the analytical standard of PLX5622 (HY-114153). This product is intended for research and analytical applications. PLX5622 is a highly selective brain penetrant and orally active CSF1R inhibitor (IC50=0.016 μM; Ki=5.9 nM). PLX5622 allows for extended and specific microglial cells elimination, preceding and during pathology development. PLX5622 is an ideal choose for microglia function research in healthy or diseased states. PLX5622 has been verified by MedChemExpress, which demonstrates desirable microglia depletion efficiency in mice. PLX5622 is predominantly administered via ad libitum diets with a dose of 1200 ppm .
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
